Caspofungin acetate - paediatric investigation plan

caspofungin acetate

Key facts

• Invented name:
  • Cancidas
  • Cancidas (previously Caspofungin MSD)
• Active Substance:
  caspofungin acetate
• Therapeutic area:
  Infectious diseases
• Decision number:
  P/30/2008
• PIP number:
  Caspofungin acetate
• Pharmaceutical form(s):
  • Powder for concentrate for solution for infusion
  • Powder for solution for infusion
• Condition(s) / indication(s):
  Fungal infections
• Route(s) of administration:
  Intravenous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  23/05/2008
• Compliance procedure number:
  EMEA-C-000010-PIP01-07-M01
• Compliance opinion date:
  04/06/2008
• Compliance outcome:
  Positive

Decision

P/30/2008: European medicines agency decision of 23 May 2008 on the application for modification of an agreed Paediatric Investigation Plan for Cancidas, caspofungin acetate, EMEA-000010-PIP01-07 MO1 in accordance with R...

AdoptedReference Number: EMEA/259268/2008